D.C. Circuit Holds That Former Purdue Pharma Executives Who Pleaded Guilty to Misdemeanor Misbranding May Be Excluded From Participation in Federal Health Care Programs


On July 27, 2012, in Friedman et al. v. Sebelius, the United States Court of Appeals for the D.C. Circuit held that the Department of Health & Human Services may exclude from participation in federal health care programs three former Purdue Pharma executives who pleaded guilty to misdemeanor misbranding of Oxycontin. Friedman is the first appellate decision to address whether a misdemeanor conviction under the Food, Drug, and Cosmetic Act can expose a defendant to permissive exclusion under 42 U.S.C. § 1320a-7(b). Friedman holds that an individual will be subject to permissive exclusion “if the conduct underlying the conviction is factually related to fraud.” The Friedman decision — a full copy of which can be found here —underscores the value of obtaining, if possible, some type of assurance from the government that HHS will not seek exclusion if a corporate or individual client agrees to plead guilty to a misdemeanor FDCA offense.

On May 10, 2007, Purdue Pharma pleaded guilty to felony misbranding, admitting to allegations that it falsely marketed Oxycontin as posing a lower risk of abuse and addiction than non-time released painkillers. On that same day, three of the company’s top executives — Michael Friedman (president), Howard Udell (general counsel), and Dr. Paul Goldenheim (medical director) — pleaded guilty, under the so-called “Responsible Corporate Officer doctrine,” to “misdemeanor misbranding . . . for their admitted failure to prevent Purdue’s fraudulent marketing of Oxycontin.” In their plea agreements, the executives disclaimed any knowledge of the fraudulent marketing of Oxycontin; they admitted only that they failed to discharge their “‘responsibility and authority to prevent in the first instance or to promptly correct’ the misrepresentations certain unnamed Purdue employees made regarding Oxycontin.”

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.